Animal Sedatives Market Size, Share and Analysis by Drug Class(Phenothiazines, Benzodiazepines,?2?adrenergic Receptor Agonists, Butyrophenones), By Application(Surgical, Diagnosis, Clinical Research Studies), By Route Of Administration(Oral, Parenteral), By Animal Type (Small, Large), By Distribution Channel(Veterinary Hospital, Clinic Pharmacies, Veterinary Retail Pharmacies, Veterinary Online Pharmacies), and Geographical Forecast, 2025-2032

The global animal sedatives market size was valued at USD 244.56 million in 2025. The market is projected to grow from USD 259.61 million in 2026 to USD 418.62 million by 2034, exhibiting a CAGR of 6.15% during the forecast period.

Animal sedatives are referred to as veterinary drugs used to sedate, calm or incapacitate an animal before proceeding for medical procedures including surgery, treatments, or administration of a drug. Animal sedatives include a large variety of sedatives such as acepromazine, phenobarbital, gabapentin, xylazine, and lidocaine. Animal sedatives play a crucial role in the prevention of diseases, pain management in animals, curing of the diseases of the afflicted animal, and treatment of the injuries. These products also help in the prevention of transmission of zoonotic diseases and in the diagnosis of animal cancers.

According to the Animal Cancer Foundation (ACF), it is estimated that 6 million dogs are diagnosed with cancer every year in the United States. Growing prevalence of the zoonotic diseases, increasing incidences of animal cancers, and growing investments in research activities by key players for the development of effective animal sedative molecules in order to enhance the safety and quality of care in animals are some of the factors likely to boost the animal sedatives market during the forecast period. 

To gain extensive insights into the market, Download for Customization

Increasing prevalence of animal diseases and growing applications of animals in medical research are the major factors likely to drive the growth of animal sedatives during the forecast period. Moreover, increasing adoption of sedative drugs used to reduce the anxiety level in animals and the enhancing the quality of care in animals during diagnostic & surgical procedures are likely to boost the animal sedatives market during the forecast period. 

However, due to the adverse effects such as reducing respiratory rate, lowering blood pressure, cardiovascular collapse, and etc., while using sedatives in animals are likely to hamper the growth of animal sedatives during the forecast period.

Key Players Covered

Some of the major companies that are present in the global animal sedatives market are Zoetis, Bayer AG, Boehringer Ingelheim International GmbH, Intervet Inc., Elanco, among others. 

Segmentation

Among drug class segmentation, phenothiazines segment is expected to hold the largest animal sedatives market share during the forecast period as they help in decreasing the dopamine levels and further depress some portions of the reticular activating systems. One of the most commonly used phenothiazines is Acepromazine which could be used alone or in conjugation with other sedatives which can be used as pre-operative medications, used to reduce travel anxiety, prevent allergies and itching in animals. 

Key Insights

Pipeline Analysis of Drugs Used As Sedatives

Epidemiology Analysis Animal Cancer/Zoonotic Disease

• The Regulatory Scenario of Key Countries/Regions
• Recent Key Industry Developments – Mergers, Acquisitions, and Partnerships.

Regional Analysis

Geographically, the global animal sedatives market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are anticipated to hold a considerable share of the global animal sedatives market owing to increasing adoption of animal sedatives, the rise in prevalence of zoonotic diseases and growing investments in medical research using animals to study pharmacokinetics and pharmacodynamics of drugs. Animal sedatives market in Asia Pacific region is anticipated to be the next fastest emerging market owing to the growing adoption of pet animals, increasing incidences of animal disorders, and growing awareness about animal welfare by government organizations. 

Key Industry Developments

• In May 2016, Zoetis received FDA approval to use SILEO (dexmedetomidine oromucosal gel) in dogs that suffer from noise aversion.
• In August 2015, Zoetis received FDA approval of SIMBADOL which provides postoperative pain control in cats for 24 hours.